Multiple myeloma cells adapt to the harsh bone marrow environment by changing their metabolism. This change affects how the cells use energy and involves a protein called NSD2. Another protein, PKCα, controls this process, making the cells less responsive to certain drugs. The study suggests that targeting the energy process influenced by NSD2 could be a potential treatment for this type of blood cancer, especially for patients resistant to certain drugs. Elevated levels of a substance called lactate in the blood could indicate this resistance.

Read more: https://pubmed.ncbi.nlm.nih.gov/37463241/